Consensus CSL Limited

Stocks

CSL

AU000000CSL8

Pharmaceuticals

Market Closed - Australian S.E. 01:10:22 2026-10-23 am EDT			5-day change	1st Jan Change
196.70 ^AUD	+0.29%		+2.34%	+13.93%

Oct. 22	Australian shares slip as Fortescue, Santos drag; banks rise	RE
Oct. 22	Australian Shares Fall; Shareholders, Others Urge APA Group to Disclose Viability of Proposed Northern Territory Gas Pipeline	MT

Evolution of the Average Target: CSL Limited

Evolution of the Target Price: CSL Limited

Changes in Analyst Recommendations: CSL Limited

ad40c0644f8f243e03e.ksjK1MEz7viJHILX-5qT-wX1K8qrWyuIHPtmhnH_seA.3pqvmYd52az-VOiYru6hwnC_Y_vlEFzlZoE8yRuNgI6lmqugjlGYz71d1w~ea147ead6ba646d3df488f25865dea30

Analysts' recommendations: CSL Limited

Oct. 07	CSL's Alentis Licensing Deal Low-Risk, Low-Reward, RBC Capital Markets Says	MT
Oct. 05	CSL's Alentis Licensing Deal Likely to Lead to Total Addressable Market of Up to Nearly $2 Billion per Year, Jefferies Says	MT
Aug. 17	CSL's Fiscal 2026 Results In Line, Jefferies Says	MT
Jun. 25	CSL, Plasma Industry Could Continue to Grow Strongly for Considerable Period, Jefferies Says	MT
May. 11	CSL's Fiscal-Year Earnings Guidance Downgrade Not Surprising, Jefferies Says	MT
Mar. 20	CSL's Business Not Threatened by CIDP Therapy Competition, Says Jefferies	MT
Mar. 01	Organic Growth in Australia's Healthcare Services Likely Due to Increased Availability of Bulk-Billing General Practitioners, Jefferies Says	MT
Feb. 10	CSL's Fiscal H1 EBIT Boosted by Cost Reductions, Jarden Says	MT
Dec. 08	CSL's China Albumin Sale to Improve in Fiscal H2 2026, Says Jefferies	MT
Nov. 10	CSL Impacted by Launch Delays, Vaccine Fatigue, Says Jefferies	MT
Nov. 06	CSL Expected to See Potential Medium-Term Earnings Upside, Says Jefferies	MT
Nov. 06	CSL's Horizon 2 Approach to 'Significantly' Boost Margins, Earnings, Jarden Says	MT
25-10-29	Jarden Research Adjusts CSL's Price Target to AU$287.14 from AU$304.17, Keeps at Overweight	MT
25-10-28	CSL Faces Macroeconomic Challenges, Will Take Time to Rerate, Says Jefferies, Shares Down 3%	MT
25-10-28	Canaccord Genuity Upgrades CSL to Buy from Hold; Price Target is AU$225	MT
25-10-28	CSL's Flu Revenue Impact for Northern Hemisphere Season Drives Guidance Downgrade, Jarden Says	MT
25-10-02	CSL to Benefit From Immunoglobin Sales Growth, Says Jefferies	MT
25-07-31	Carlisle Faces Downgrade From Loop Capital; Shares Fall	MT
25-07-11	CSL Shares Fall Amid Target Price Cut by Morgans Financial	MT
25-07-10	Morgans Financial Upgrades CSL to Buy from Add; Price Target is AU$303.70	MT
24-10-24	CSL's R&D Day "Uninspiring," Jarden Research Says	MT
24-09-08	CSL 'Strong Franchise in Medium Term' Amid Higher Fiscal 2024 Earnings, Jefferies Says	MT
24-09-04	Carlisle Expected to Show Solid Growth, Margin Expansion, Oppenheimer Says	MT
24-08-14	Jarden Research Adjusts CSL's Price Target to AU$329.62 From AU$305.34, Keeps at Overweight	MT
24-03-05	Morgan Stanley Adjusts CSL’s Price Target to AU$310 From AU$318, Keeps at Overweight	MT

More recommendations

Biopharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	CSL LIMITED					-5.45%
	ELI LILLY AND COMPANY					+4.56%
	JOHNSON & JOHNSON					+5.91%
	ABBVIE INC.					-0.3%
	ROCHE HOLDING AG					-1.29%
	MERCK & CO., INC.					+9.97%
	NOVARTIS AG					-3.4%
	ASTRAZENECA PLC					+22.47%
	AMGEN INC.					-9.69%
	GILEAD SCIENCES, INC.					+2.66%
	Average					+2.54%
	Weighted average by Cap.					+3.61%